Are probiotics a feasible intervention for prevention of diarrhoea in the developing world?
With more than 1.4 million of the 9 million child deaths being attributed to diarrhoea in 2008 and 49% of them occurring in five countries namely, India, Nigeria, Democratic Republic of the Congo, Pakistan and China, there is an urgent need for intervention to prevent and control diarrhoeal diseases. Of the various interventions, probiotics offer immense potential. The past decade has witnessed the validation of their utility for the prevention, treatment and management of a variety of infective and non infective disorders. The most investigated field continues to remain infectious diarrhoea and compelling evidence comes from randomized placebo controlled trials. While results from these studies are encouraging most of them reflect the outcomes of the developed world. Developing countries like India continue to struggle with nutritional and health challenges and bear the greatest burden of diarrhoea. A paucity of data from the developing countries limits the definite recommendation of probiotics. In these countries curd, often confused for a probiotic, is practiced as an integral part of the culture. While the nutritional benefits of these products cannot be understated, it is still uncertain whether these products can be classified as a probiotic. The emergence of probiotic foods which are scientifically validated for their efficacy and impart defined health benefits offer an excellent opportunity to improve public health. A recent randomized controlled trial conducted by the National Institute of Cholera and Enteric Diseases in Kolkata, India demonstrated a protective efficacy of 14% in preventing diarrhoea among children who received a probiotic. For the developing world however the vision for probiotics would mean a fundamental change in perception and developing a well planned strategy to allow interventions like probiotics to permeate to impoverished settings, where the assault of micro organisms is on a daily basis. This would mean that probiotics are ingrained into the public health system without being seen as a medicine.
Hajela
Neerja
N
National Institute of Immunology, New Delhi - 110 067, India. nkganguly@nii.res.in.
Nair
Gopinath B
GB
Ganguly
Nirmal K
NK
J Pediatr Gastroenterol Nutr. 2000 Jan;30(1):54-60
10630440
J Clin Gastroenterol. 2007 Sep;41(8):756-60
17700424
BMC Pediatr. 2004 Sep 02;4:18
15345099
J Pediatr Gastroenterol Nutr. 2001 Oct;33 Suppl 2:S17-25
11698781
Aliment Pharmacol Ther. 2002 Aug;16(8):1461-7
12182746
Paediatr Drugs. 2005;7(2):111-22
15871631
Int J Epidemiol. 2008 Aug;37(4):816-30
18567626
Eur J Pediatr. 2007 Apr;166(4):311-8
17287932
J Paediatr Child Health. 2007 Dec;43(12):837-42
17803667
J Trop Pediatr. 2009 Oct;55(5):297-301
19203988
J Appl Microbiol. 2007 Apr;102(4):1026-32
17381746
Science. 2005 Jun 10;308(5728):1635-8
15831718
Pediatrics. 2002 Apr;109(4):678-84
11927715
Lancet. 2010 Jun 5;375(9730):1969-87
20466419
Lancet Infect Dis. 2006 Jun;6(6):374-82
16728323
BMJ. 2002 Jun 8;324(7350):1361
12052801
Eur J Clin Nutr. 2002 Dec;56 Suppl 4:S56-9
12556949
Dig Dis Sci. 2002 Nov;47(11):2625-34
12452406
Lancet. 2010 Mar 13;375(9718):870-2
19833382
J Pediatr Gastroenterol Nutr. 1997 Nov;25(5):516-9
9360205
J Pediatr Gastroenterol Nutr. 2003 Jan;36(1):112-5
12500005
Lancet. 2009 Sep 19;374(9694):1032-1035
19766883
Lancet. 2010 Jul 3;376(9734):63-7
20609988
Indian J Pediatr. 2005 Nov;72(11):935-8
16391447
Epidemiol Infect. 2011 Jun;139(6):919-26
20670468
Pediatrics. 2005 Aug;116(2):e221-8
15995003
Cochrane Database Syst Rev. 2004;(2):CD003048
15106189
Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004827
17443557